Clinical trial
A phase II, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280a (Anti-PD-L1 Antibody) compared with docetaxel in patients with Non-Small Cell Lung Cancer after platinum failure
To estimate the efficacy of MPDL3280A compared with docetaxel as measured by OS
To evaluate the safety and tolerability of MPDL3280A compared with docetaxel
| Category | Value |
|---|---|
| Study start date | 2013-08-08 |